According to conventional neovascularization concepts, due to local tissue factors, a viable graft of central nervous (CNS) tissue should be expected to retain a complete blood-brain barrier (BBB) in its new site. In order to determine if grafted CNS would alter the phenotype of ingrowing peripheral vessels we have used an uncomplicated model. Rat fetal cortex, which already has a BBB to protein, was grafted to the subcapsular space of the host rat kidney. After postoperative times between 4 weeks and 3 months, horseradish peroxidase was injected systemically for periods between 90 s and 4 min. Correlative electron microscopy depicted vascular morphology. Each graft contained protein exudation particularly around large vessels in the neuropil. At the EM level some of the vascular endothelia had fenestrations, were invested with collagen, and were not contacted by astroglia. Capillaries indigenous to the CNS grafts and related normally to astroglial end feet were also prominent. The presence of non-CNS vessels with peripheral ultrastructural and permeability characteristics would appear to contradict conventional theory in that CNS grafts can be vascularized by vessels of a different phenotypic and physiologic nature.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0014-4886(89)90042-3 | DOI Listing |
Zool Res
January 2025
Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, Guangdong 510280, China. E-mail:
Severe combined immunodeficiency disease (SCID), characterized by profound immune system dysfunction, can lead to life-threatening infections and death. Animal models play a pivotal role in elucidating biological processes and advancing therapeutic strategies. Recent advances in gene-editing technologies, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR/Cas9, and base editing, have significantly enhanced the generation of SCID models.
View Article and Find Full Text PDFCNS Neurosci Ther
January 2025
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Background: Alzheimer's disease (AD) is a debilitating neurodegenerative disorder that is difficult to predict and is typically diagnosed only after symptoms manifest. Recently, CD4 T cell-derived double-negative T (DNT) cells have shown strong immuno-regulatory properties in both in vitro and in vivo neuronal inflammation studies. However, the effectiveness of DNT cells in treating on AD are not yet fully understood.
View Article and Find Full Text PDFTurk Neurosurg
March 2024
SBÜ Gaziosmanpaşa Eğitim ve Araştırma Hastanesi.
Erdheim-Chester Disease is a rare systemic xanthogranulomatous infiltrating disease, characterized by lipid-laden histiocytes accumulating in various organs and almost always in bones. Etiology of the disease is still unknown. It may involve various organs and systems, such as musculoskeletal, cardiac, pulmonary, renal, gastrointestinal and central nervous system (CNS) as well as the skin.
View Article and Find Full Text PDFCancer Manag Res
January 2025
Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China.
The chronic myeloid leukemia (CML) is easily diagnosed by laboratory examination, however, rare BCR-ABL1 mRNA transcripts variants, such as e1a3 present diagnosis and therapeutic challenges. This case report details the diagnosis and management of a CML patient with the e1a3 transcript by FISH and RT-PCR. Following initial diagnosis, the patient was treated with the tyrosine kinase inhibitor (TKI) Flumatinib.
View Article and Find Full Text PDFAnn Hematol
January 2025
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing, China.
Experience using olverembatinib as maintenance therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) after allogeneic hematopoietic cell transplantation (allo-HCT) is limited. We retrospectively collected data from 26 patients with Ph ALL who received only olverembatinib as maintenance therapy after allo-HCT. Olverembatinib was administered as prophylaxis in 18 patients (69.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!